229 related articles for article (PubMed ID: 29662195)
1. NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth.
Seidi K; Jahanban-Esfahlan R; Monhemi H; Zare P; Minofar B; Daei Farshchi Adli A; Farajzadeh D; Behzadi R; Mesgari Abbasi M; Neubauer HA; Moriggl R; Zarghami N; Javaheri T
Oncogene; 2018 Jul; 37(29):3967-3980. PubMed ID: 29662195
[TBL] [Abstract][Full Text] [Related]
2. RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice.
Jahanban-Esfahlan R; Seidi K; Monhemi H; Adli ADF; Minofar B; Zare P; Farajzadeh D; Farajnia S; Behzadi R; Abbasi MM; Zarghami N; Javaheri T
Sci Rep; 2017 Aug; 7(1):8126. PubMed ID: 28811469
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of an Integrin α
Gai Y; Jiang Y; Long Y; Sun L; Liu Q; Qin C; Zhang Y; Zeng D; Lan X
Mol Pharm; 2020 Jan; 17(1):349-358. PubMed ID: 31829615
[TBL] [Abstract][Full Text] [Related]
4. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.
Bieker R; Kessler T; Schwöppe C; Padró T; Persigehl T; Bremer C; Dreischalück J; Kolkmeyer A; Heindel W; Mesters RM; Berdel WE
Blood; 2009 May; 113(20):5019-27. PubMed ID: 19179306
[TBL] [Abstract][Full Text] [Related]
5. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.
Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE
Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706
[TBL] [Abstract][Full Text] [Related]
6. A CD13-targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis.
Zheng YB; Gong JH; Liu XJ; Li Y; Zhen YS
Mol Carcinog; 2017 May; 56(5):1395-1404. PubMed ID: 27991698
[TBL] [Abstract][Full Text] [Related]
7. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
[TBL] [Abstract][Full Text] [Related]
8. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
Curnis F; Arrigoni G; Sacchi A; Fischetti L; Arap W; Pasqualini R; Corti A
Cancer Res; 2002 Feb; 62(3):867-74. PubMed ID: 11830545
[TBL] [Abstract][Full Text] [Related]
9. Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR.
Brand C; Fröhlich M; Ring J; Schliemann C; Kessler T; Mantke V; König S; Lücke M; Mesters RM; Berdel WE; Schwöppe C
Mol Pharm; 2015 Oct; 12(10):3749-58. PubMed ID: 26310827
[TBL] [Abstract][Full Text] [Related]
10. An antimicrobial peptide containing NGR motif has potent antitumor activity against CD13+ and CD13- tumor cells.
Zhang Z; Hou L; Feng L; Huang S; Luo M; Shao S; Zhang X; Gu S; Zhao X
Tumour Biol; 2015 Sep; 36(10):8167-75. PubMed ID: 25990455
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of antimicrobial peptides containing CisoDGRC in CD13 negative breast cancer cells.
Hou L; Zhao X; Wang P; Ning Q; Meng M; Liu C
PLoS One; 2013; 8(1):e53491. PubMed ID: 23326440
[TBL] [Abstract][Full Text] [Related]
12. In vivo NIRF imaging-guided delivery of a novel NGR-VEGI fusion protein for targeting tumor vasculature.
Ma W; Li G; Wang J; Yang W; Zhang Y; Conti PS; Chen K
Amino Acids; 2014 Dec; 46(12):2721-32. PubMed ID: 25182731
[TBL] [Abstract][Full Text] [Related]
13. In vivo tumor targeting by a NGR-decorated micelle of a recombinant diblock copolypeptide.
Simnick AJ; Amiram M; Liu W; Hanna G; Dewhirst MW; Kontos CD; Chilkoti A
J Control Release; 2011 Oct; 155(2):144-51. PubMed ID: 21763734
[TBL] [Abstract][Full Text] [Related]
14. Co-Administration of Vadimezan and Recombinant Coagulase-NGR Inhibits Growth of Melanoma Tumor in Mice.
Daei Farshchi Adli A; Jahanban-Esfahlan R; Seidi K; Farajzadeh D; Behzadi R; Zarghami N
Adv Pharm Bull; 2021 Feb; 11(2):385-392. PubMed ID: 33880362
[No Abstract] [Full Text] [Related]
15. Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth.
Yokoyama Y; Ramakrishnan S
Cancer; 2005 Jul; 104(2):321-31. PubMed ID: 15952188
[TBL] [Abstract][Full Text] [Related]
16. NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells.
Wang X; Wang Y; Chen X; Wang J; Zhang X; Zhang Q
J Control Release; 2009 Oct; 139(1):56-62. PubMed ID: 19470394
[TBL] [Abstract][Full Text] [Related]
17. CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.
Schmidt LH; Stucke-Ring J; Brand C; Schliemann C; Harrach S; Muley T; Herpel E; Kessler T; Mohr M; Görlich D; Kreuter M; Lenz G; Wardelmann E; Thomas M; Berdel WE; Schwöppe C; Hartmann W
Lung Cancer; 2017 Nov; 113():121-127. PubMed ID: 29110838
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and activity evaluation of a new 5-fluorouracil prodrug containing an Asn-Gly-Arg(NO2)COOCH3 tripeptide.
Luan Y; Jing F; Zhang J; Zou M; Wang X; Jia Y; Liu N; Mou J; Xu W
Protein Pept Lett; 2012 Oct; 19(10):1122-31. PubMed ID: 22512656
[TBL] [Abstract][Full Text] [Related]
19. Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma.
Brand C; Greve B; Bölling T; Eich HT; Willich N; Harrach S; Hintelmann H; Lenz G; Mesters RM; Kessler T; Schliemann C; Berdel WE; Schwöppe C
PLoS One; 2020; 15(2):e0229271. PubMed ID: 32084238
[TBL] [Abstract][Full Text] [Related]
20. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
Sheng W; Shang Y; Li L; Zhen Y
Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
